High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial

MeSH terms

• Acute Coronary Syndrome* / genetics
• Acute Coronary Syndrome* / mortality
• Acute Coronary Syndrome* / therapy
• Adenosine / administration & dosage
• Adenosine / adverse effects
• Adenosine / analogs & derivatives*
• Adenosine / pharmacokinetics
• Aged
• China / epidemiology
• Clopidogrel
• Cytochrome P-450 CYP2C19 / genetics*
• Dose-Response Relationship, Drug
• Drug Monitoring / methods
• Female
• Hemorrhage* / chemically induced
• Hemorrhage* / diagnosis
• Humans
• Kaplan-Meier Estimate
• Long Term Adverse Effects* / diagnosis
• Long Term Adverse Effects* / etiology
• Long Term Adverse Effects* / mortality
• Male
• Middle Aged
• Percutaneous Coronary Intervention / methods
• Pharmacogenomic Testing / methods
• Purinergic P2Y Receptor Antagonists / administration & dosage
• Purinergic P2Y Receptor Antagonists / adverse effects
• Purinergic P2Y Receptor Antagonists / pharmacokinetics
• Ticagrelor
• Ticlopidine / administration & dosage
• Ticlopidine / adverse effects
• Ticlopidine / analogs & derivatives*
• Ticlopidine / pharmacokinetics
• Treatment Outcome